778
KLINICKÁ341804301074588109168189242288347
FARMAKOLOGIE709804301074291138211265312372415474533554598
A13288043010753
FARMACIE1403804301074191138210265316336380
/18298043010732
Klin190680430107446583131
Farmakol2057804301074278105179220258305325
Farm2402804301074178104179
2023;37(3):115-1182601804301074386128172186230270290333354368406440478505544578617
/32638043010732
www.klinickafarmakologie.cz4568804301076513320121425327329234035839843647950254457164568672477179183988990895196610061045
1181378026012657107161
PŘEHLEDOVÉ341207012660124182256312369444520587645
ČLÁNKY1008207012660115187259327395
Lokálna34136501062968104146177219258
liečba6153650106294779113149190
bazocelulárneho82036501063474108147182214246286317358394435467508549
karcinómu138536501063375111145163204245299339
–1740365010645
súčasný180136501063071105147181222259
stav20763650106306399134
a2226365010638
nové227936501063980118149
perspektívy244436501063364100134169200236270288326365
6.3436200853652
Geisse416621083448095122149184
J,6216210832437
Caro678621083417495133
I,8326210831528
Lindholm881621083314785125163202218276
J,11786210832537
et12366210833456
al.1313621083324861
Imiquimod1395621083157389128166181240278318
5%17346210833586
cream1841621083315387120178
for343721083185678
the439721083226095
treatment552721083224377109131189224262284
of8547210833857
superficial9297210832764103138160180197229244276291
basal1239721083387198131146
cell140472108331658095
carcinoma:1518721083316485116131169207266298310
Results18477210833570971341493438210832250
from414821083184178137
two5728210832275113
phase7068210833978111138173
III,90082108315304659
randomized,979821083215593132171230245275309349362
vehicle-controlled13628210833266105120153168204227261298337359381419435450485525
studies.1908821083265088343921083395591119133
Journal4989210832464104126166199215
of7359210833858
the815921083226198
American93492108342102138161177210244284
Academy12399210834275109149185245277
of15389210833858
Dermatology.16189210834683105165199221260276316357390401
2004;50(5):722-733.34310210833468104141152188222241275293305338373407428459493526539
7.34311200853645
Roldán-Marín4081121083357490129161199222278311332348386
R,81511210833549
Toussaint-Caire88511210833266105131158191206244266286329362377398432
S.133811210833246
Imiquimod14041121083157388127165180238276316
5%174111210833485
as184611210833259
adjuvant1925112108332713431221083155285118156178
therapy5391221083226095116149188220
for7771221083195678
incompletely8731221083155385122180219235270292326342373
excised12651221083346697112138173212
infiltrative1496122108315537087102124146179201216249283
nodular179712210833876116153169201222
basal3431321083397298131147
cell504132108331648095
carcinoma6131321083316485116131169207266298
and92513210833270109
dermoscopy10481321083387294152191217249286326357
to141913210832259
monitor149113210835896135150172209231
treatment17351321083224377109131189224262284
response.3431421083215582120159198224259271
Dermatology63014210834580102160192214251267305345377
and102214210833270109
Therapy.114614210833372107128161200232242
2015;5(4):265-272.140314210833468100130141176194227244256291325358380411444479491
8.34315200853651
McKay41015210835486121153184
KM,60915210833591104
Sambrano72915210833265122160181214251288
BL,10331521083366780
Fox11291521083326999
PS,12431521083366880
et133915210833455
al.14101521083324759
Thickness14851521083327185116146184219245271
of177215210833755
superficial184315210832663101136157343162108317346580111126
basal4871621083397197129144
cell649162108332658094
carcinoma7611621083326484115129166204261293
(SBCC)10731621083184983124161181
predicts12721621083396093132146178201228
imiquimod15191621083147186124161175232270309
efficacy:18461621083345270871191513431721083316477
A431172108341
proposal4841721083385996135173199231246
for7411721083195677
a829172108332
thickness-based8731721083215973104133172206232258278318350376410449
definition13331721083397389106144158180194231269
of161417210833756
SBCC.168117210833367107144157
British1849172108336567193108133170
Journal3431821083246299120158189204
of56118210833756
Dermatology.63118210834579100158189210247262299338370379
2013;169(3):549-554.10241821083346798128138168198231250283299311345380412435468500534546
9.34319200853649
Roozeboom41119210833574112141175214253291350
MH,78019210835499112
Arits9111921083416278100128
AHHM,105819210834185130185198
Nelemans12751921083458096131189221259285
PJ,15791921083355567
et166519210833456
al.17401921083324760
Overall181919210834781115136169184199
treatment3432021083224377109131189224262284
success6412021083266396126160187214
after8692021083325176110131
treatment10142021083224478109131189224262284
of131320210833756
primary13842021083386076133166187221
superficial161920210832664103138160179196229244276291
basal1925202108338713432121083265975
cell432212108331648095
carcinoma:5412121083316485116131169208266298310
A865212108341
systematic9202121083265986109143201233255270302
review12362121083205487102137188
and143821210833270109
meta-analysis156121210835792115147170202240272288320347361388
of196221210833857
randomized3432221083205390128166223238267300339
and69422210833269107
nonrandomized81422210833774112133165202241278336350379412451
trials.1277222108322435889104130143
British1432222108335567193108133171
Journal16152221083246199120157189204
of183122210833756
Dermatology.18992221083458010134323210835790111148164202242274284
2012;167(4):733-756.64223210833569100130143173204237253286304315349383416438469502536549
10.3432420085366984
Sharquie43924210833269101122159196211245
KE,6972421083346881
Noaimi79024210834582115130187201
AA.10042421083408397
Basal11142421083356793126141
cell1267242108331648094
carcinoma:13742421083316384114129166204262293305
Topical169224210833265104120151183198
therapy190324210832159933432521083205391122
versus4772521083316585112148174
surgical6632521083266283120135166198213
treatment.8882521083224376107128185220257278291
Journal11912521083246199119157189204
of140725210833755
the14752521083215893
Saudi158025210833264101139154
Society174625210833270102116150172205
of196325210833756
Dermatology34326210834581102160193214251267305345377
&73326210833972130169181
Dermatologic92726210834681102161193215252268306345361393
Surgery.13332621083326990129163185219229
2012;16(2):41-51.157526210833468100130142172203222256274286320351369403434444
11.3432720085356576
Kim43127210833450107
JYS,5502721083235990102
Kozlow6642721083357199114151201
JH,8772721083246780
Mittal9692721083536890113145160
B,114127210833547
et120027210833455
al.12672721083314659
Guidelines13382721083438094132166181196232267293
of164327210833655
care17102721083316383116
for18382721083185576
the19262721083215892
management34328210835790128160199234292327365387
of74528210833857
basal8182821083387198131146
cell980282108331658196
carcinoma.10922821083316485116131169207266298311
Journal141928210832462101122160193208
of164328210833756
the17152821083226095
American18262821083419913415517134329210833164102
Academy46029210834173106145180238268
of74429210833756
Dermatology.81529210834681102161193215252268306345377388
2018;78(3):540-559.121829210833468100131143176209228262279291326362397421455488520531
12.3433020085366782
van43730210833164101
Delft5503021083458095114138
LCJ,7013021083316995106
Nelemans8203021083447894128185217254280
PJ,11123021083355466
Kessels11903021083346894120155170196
JPHM,139830210832459102156169
et158030210833355
al.16483021083314658
Long-term171930210833168105144166188221241299
efficacy343312108334527088120153185219
of57831210833857
photodynamic65231210833877115137174213245284316374389421
therapy10903121083226095116149188219
with13263121083516689127
fractionated14703121083184073105129145183221253275309348
5-aminolevulinic183531210833456881461613433221083387692127159197213228265280312
acid6703221083326479118
20%80332210833468121
versus9393221083326687114152178
conventional113232210833168106138172210231247285323355371
two-stage151832210832174112135162185218257292
topical18253221083225998114146178194
methyl34333210835792115153183200
aminolevulinate55733210833289105142181197231264302317332370403424458
for10293321083195678
superficial112133210832664103138159179196228243275291
basal-cell14263321083397298131147169203236252267
carcinoma.17073321083326486117132170208266299312
Dermatology.34334210834581102160193214251267305345377387
2022;238(6):1044-1049.74534210833569101136149184218253272305323335365396432469492523555591624635
13.3433520085377186
Ceilley4513521083417692109125161194
RI,6673521083365366
Del75535210834784100
Rosso87735210833676104132172
JQ.10713521083247487
Current118035210834179101124159199222
modalities142335210835999141174191207230246283311
and175535210833373113
new189035210833975128
advances34336210833271104136174207240267
in62436210831452
the6903621083216094
treatment7983621083224377109131189224262284
of109536210833757
basal11653621083397298131147
cell1325362108332658196
carcinoma.14343621083326586117132170208266299312
International1759362108315537510913016820122223834337210833776108123
Journal48237210832462100121160192208
of70537210833757
Dermatology.77737210834581102160193214251267305345377387
2006;45(5):489-498.117937210833469105140153187220238271290302336372406430467500535548
14.3433820085356782
Habashy43638210834375113145170207236
S,68438210833244
Jafri740382108324557394109
A,86138210834054
Osman92738210834672128159196
HO,113538210834390100
et124738210833355
al.13143821083314658
Hedgehog138438210834377115153187224261299
pathway16953821083387091128177209239
inhibitors:1946382108314513433921083375291106129165187214226
Clinical5823921083395469107121153186201
implications79639210831471110126141173205227242279318344
and115239210833270108
resistance1273392108321548196121144177215247280
in156639210831452
the16303921083226095
treatment17373921083224377108130188222260281
of21386210833757
basal2210621083397298131147
cell237262108331658096
carcinoma.2483621083316485116131169207266298311
Cureus.2810621083407697131169195209
2021;13(3):13859.30346210833469101133141171201219253270282312342376410442453
15.2138720085366780
Nguyen22307210834482119149182219
NM,24607210834598111
Cho25827210833976113
J.27067210832435
Hedgehog27527210834478116154188225262300
pathway3063721083387091128177208238
inhibitors3312721083145188102140154176211232258
as35817210833157
targeted36497210832153731101442138821083225594
cancer22448210833163100132165185
therapy2442821083215993114146184215
and26698210833269108
strategies2789821083264869102123156194209243269
to30708210832258
overcome31408210833869102123153190247282
drug3434821083385896134
resistance.3580821083215481951201431752122138921083316374
International2223921083155171104124161192212227263300331345
Journal2579921083246197117155185200
of27909210833654
Molecular28559210835491106139171207221252272
Sciences.3138921083326377110147177210235248
2022;23(3):1733.3396921083346798132143177210227259275286314342375407418
16.21381020085366985
Gambini223810210834476134173189227242
D,249510210834556
Passoni25661021083356793120158196211
E,279210210833346
Nazzaro285310210834477106137171192229
G,309710210834457
et316910210833456
al.32401021083324760
Basal33151021083356894128143
cell3473102108331658095
carcinoma35831021083316485116131169208213811210835789
and224011210833169108
hedgehog236011210833872112150185223261300
pathway26721121083397293131181213244
inhibitors:29291121083145289104143158181217239266278
Focus322011210833269101139165
on339711210833775
immune348511210831572129166204239
response.373711210832054213812210832665104142169204216
Frontiers23691221083335289128149165199221248
in263212210831553
Medicine.270012210835590129144176191229264276
2022;9.299212210833468101136148183194
17.21381320085366876
Yin22301321083355189
VT,23341321083367382
Sniegowski24311321083337086120160198249276306322
M,276813210835568
Esmaeli285213210833260117150185200215
B.308313210833548
Indications31461321083155392107139172194209247286312
and347313210833270109
limitations35971321083153088103125158180195213814210833776102
of225614210833857
vismodegib23291421083324874132170210244284299338
for26841421083185677
basal27781421083387198131146
cell2941142108331658095
carcinoma.30531421083316485116131169207266298311
JAMA338114210832464120161
Ophthalmology.355914210834787125147185217233213815210835796112150189221231
2014;132(7):905-906.238515210833468100131143173203235253287307319354389424446481516552565
18.21381620085366985
Cozzani224316210834077105136170208223
R,248516210833650
Aguila255416210834179117132147179
R,275316210833549
Carrizo28221621083397293115131160197
M,303916210835467
et312616210833456
al.32011621083324861
Efficacy3281162108333506886118151183217
and351716210833270109
safety36451621083266078113135169
profile21381721083396097115132147182
of233617210833857
vismodegib24091721083324874131170209244284299338
in276317210831553
a2832172108332
real-world28801721083215587102124176214236251290
setting31871721083266183107123160199
cohort340317210833168106145166191
of361017210833857
patients3683172108339729410921381821083347294121
with22731821083516689127
advanced241418210833271104136175207240280
basal27081821083397298131147
cell2869182108331658095
carcinoma29781821083316485117132169208266298
in329018210831553
Argentina.335718210834162100135173195210248280294
International3665182108314527410812921381921083387092107145183216231
Journal238419210832463101122161193208
of260819210833756
Dermatology.268019210834580101160192214251267305345377387
2020;59(5):627-632.308219210833468101135148183215235268286298334367400419456490522535
19.21382020085366778
ClinicalTrials.gov.22272021083405366103116146177191223239253283297321333370406437445
Trial2682202108332486292106
of279720210833755
Patidegib2862202108335658599136169206220257
Gel31292021083437791
2%,32302021083348496
4%,33362021083348395
and344120210833167105
Vehicle355520210833667103117147160193
to375820210832257
Decrease213821210834578108127159189213246
the23932121083225790
Number249321210834379134171204223
of272621210833754
Surgically27892121083326786122135165196209222252
Eligible3050212108332455895108145159191
Basal32512121083346590120134
Cell3394212108340718598
Carcinomas35012121083397089118131167203258288313
in213822210831551
Gorlin220022210834381101115129165
SynDrome23762221083336198143163199256290
Patients26762221083356686100133170190216
–2903222108335
Full2949222108332678195
Text30542221083336292115
View.31802221083365184134143
[cited3334222108318476182114152
202334972221083346798132
Mar363922210835586105
1].37552221083344859
Available213823210834069100113126156193207240
from:23872321083183873129140
https://clinicaltrials.gov/ct2/show/NCT02762084.253623210833757791161411511761952212352482832973263573713914104244544674915035405766056276536757097337567918278768989419801013104510761107113711681200123312671278
20.21382420085367288
ClinicalTrials.gov.22472421083405571109124156189205239256272304320346360399437470480
Clinical27472421083405671109124156189205
Trial2973242108332506598113
of310724210833757
Patidegib31842421083366890105144179219234274
Gel34782421083448096
2%,359424210833587101
4%,371524210833586100
and213825210833271110
Vehicle226925210833670109124157172208
Applied249825210834181121137153188228
Once274725210834887120154
or292225210833860
Twice30032521083338096129163
Daily31872521083467994110142
to335025210832259
Decrease343025210834682115137172204231267
the37182521083226096
GLI121382621083447691123
Biomarker22752621083365189147180201231266287
in257726210831452
Sporadic264426210833271110132165204219251
Nodular291026210834483122160175207228
Basal31532621083366995128144
Cell33112621083407490105
Carcinomas34312621083397293124140177216274306333
–3779262108335
Full2138272108332698499
Text22542721083326394119
View.23892721083365287138149
[cited2554272108319496487120160
2023273027210833469101136
Mar288327210835487108
1].30072721083345062
Available308527210834172105120135167207222257
from:33592721083184077136148
https://clinicaltrials.gov/ct2/show/NCT02828111.35232721083385984123150162189210238254269213828210833853851171331551771922242402662793183563884114404645005275515896276787027487898248588919259589921024105210791089
21.21382920085377387
Villani2249292108337557289123163180
A,245329210834258
Potestio25352921083367599135164189206246
L,280529210833247
Fabbrocini287629210833465107149172212247263304320
G,322029210834560
et330429210833559
al.33872921083335065
New347529210834684138
emerging36362921083359613415721383021083395594135
treatment22953021083224580113136196233272295
options261230210833879103119159198226
for28603021083195881
advanced296330210833373107142181215250291
basal327630210833974101136153
cell34513021083326783100
carcinoma35733021083326688121137176216213831210835892
and225231210833271112
squamous238631210832667106139199238278305
cell27133121083326784100
carcinoma.28353121083326688120136176215275309323
Advances318031210834281115149189222257285
in348731210831554
Therapy.356431210833373109132166206239250
2022;39(3):1164-1178.213832210833469103138151187221241275293305336364396433457488517547581595
22.21383320085367288
Verkouteren22403321083366890120158196218252273307345
BJA,259833210833660100114
Sinx27253321083334885117
KAE,285533210833579112125
Reinders29933321083357086123162197219246
MGHC,325233210835499143184197
et346233210833457
al.35323321083314760
Update360533210834382122154176210
on213834210833774
hedgehog222534210833771109148182219257295
pathway25323421083397192129179211241
inhibitor27853421083155289103142157179215236
therapy30333421083215893113146184214
for32603421083185576
patients33483421083387091106140177198225
with35853421083506587124
basal37223421083387021383521083265975
cell2227352108332658196
naevus233835210833769104137175201
syndrome25543521083265998137158195253288
or285735210833759
high-frequency29303521083385392130152172194228268305340378410444
basal33893521083387198131146
cell3550352108331658196
carcinoma.36603521083326486117132213836210833876134166180
Acta23333621083417297129
Dermato-Venereologica.247836210834580102160192214251274310343381416437471510526564604619651684697
2022;102:980.319036210833468101136148178210243255290325361373
23.21383720085367287
Zeng224337210833871110149
L,240937210833145
Gowda247237210834382133172204
BH,26943721083358093
Ahmed280437210834179137172212
MG,303337210835599113
et316337210833456
al.32373721083324760
Advancements331537210834179112144182215248306341379401429
in376137210831553
nanoparticle-based213838210833870109148188221243267283315331366390430463490526566
treatment27243821083224478111133192227266287
approaches303238210833272112134171205237276311338
for33913821083185778
skin34903821083275773112
cancer362338210833164103135169191
therapy.21383921083226095116149188219229
Molecular238339210835493109143176214229261282
Cancer.268139210834073111143176198208
2023;22(1).290439210833469101136148183217235266281292
24.3934620085367186
Souto40346210833271109131168
EB,4216621083336981
Macedo43116210835587119153193231
AS,4556621083417588
Dias-Ferreira4658621083456193119140174208229251285300322355
J,50276210832436
et50776210833456
al.5147621083324760
Elastic5221621083334880107130145177
and54126210833270109
ultradeformable553562108337533934721083224376115150169207228287319358374409
liposomes4360721083153069108135173231266293
for4670721083185678
transdermal4765721083214376114140179214235294326341
delivery5123721083387389104136171192226
of53667210833756
active5439721083326489104136171
pharmaceutical39348210833978111132191224257291329352368400433449
ingredients4404821083155393114149189204239278300328
(apis).4753821083184989105131149160
International4934821083155375109131170203225240279318350366
Journal53218210832463102123162195211
of55538210833757
Molecular39349210835493109144176214229262283
Sciences.4232921083336580115153185219245259
2021;22(18):9743.45069210833469101133141176211228260291309321356389419452464
25.39341020085367287
Zielińska40391021083385388103118156182212246
A,430210210834155
Szalata43741021083336195110143164197
M,458810210835568
Gorczyński467410210834382104135165199238264294311
A,500210210834155
et507410210833457
al.51481021083324760
Cancer522510210834073111143177198
nanopharmaceuticals:544110210833769108146393411210833876108129186218249282320342357388420435461473
Physicochemical441911210833572102128143174210242280314371386417449464
characterization489611210833168100120153184208241262277305338360374412450
and535811210833169107
in547711210831552
vitro/in55421121083314639341221083224380105121159
vivo41081221083324880118
applications.424112210833271111127142174206228243281320346360
Cancers.461612210834073111143177198225239
2021;13(8):1896.487012210833468101133141171201219253271283313344378413427
26.39341320085367288
Calienni40431321083407489105140178217232
MN,4296132108355101114
Febres-Molina443113210833367107129164191212269308324340378411
C,486313210834053
Llovera49371321083324886119154175209
RE,51671321083357083
et527113210833457
al.53491321083324761
Nanoformulation54301321083467811715639341421083185678136174189221243258296335
for42881421083195678
potential438514210833978100134172193208240256
topical46601421083225999114146179194
delivery48741421083387389104136170192226
of511914210833757
Vismodegib51951421083365279136174214249289304343
in555714210831553
skin39341521083265672110
cancer406315210833164102134168189
treatment.42701521083224378109131189224262284297
International45861521083155374108129168200222237275313346361
Journal496615210832462100121160192208
of519215210833757
Pharmaceutics.5267152108335731051261842172492833203934162108322376997110
2019;565:108-122.405916210833569101131143179213247258287319354377408438472485
27.39341720085367180
Morton403417210835493114139176214
CA,42681721083408397
Dominicus438517210834584142157195210242280306
R,471117210833549
Radny478017210833668108146176
P,497617210833540
et503617210833456
al.51121721083314760
A5192172108341
randomized,52521721083215492131169228243272306345358
multinational,393418210835896112135150189222244259298337370385398
noninferiority,435318210833877116131170189224245261300322338361395405
phase477918210833978111138173
III49731821083153146
trial5040182108322446092108
to516918210832259
evaluate524918210833567101117155188210244
the55141821083226096
safety39341921083276180115138173
and412819210833271111
efficacy4260192108335547290123157190224
of450519210833858
BF-20045841921083367092124158195
aminolaevulinic480119210833291107145185201234270303342358373412428461
acid52831921083326581120
gel54251921083387490
vs.55361921083326074
methyl393420210835893115154185201
aminolaevulinate415520210833290106144182198231266298337352367406438460494
cream46692021083325388120178
in486720210831553
the49412021083216095
treatment50572021083214377109131190225263285
of536320210833756
nonaggressive54402021083387611514739342121083387798132159186201233267
basal42162121083397299132147
cell4378212108331658196
carcinoma44892121083316485116131169207265298
with48022121083506688127
photodynamic494421210833877115137174213245284316374389421
therapy.53802121083226095116149189220230
British3934222108335577295110136174
Journal412322210832463101122161193208
of434722210833756
Dermatology.441922210834580101160192214251267305345377387
2018;179(2):309-319.482122210833468100131143173203236255289307319354389424447480511541552
28.39342320085367288
Mohammadpour403623210835493131164221279312351390429467488
R,453823210833549
Dobrovolskaia460123210834584124145182214252268294324357372404
MA,501923210835597111
Cheney514423210834077112150185217
DL,53752321083457791
et548023210833456
al.55502321083324760
Subchronic393424210833270109142180201238276292324
and427324210833270109
chronic43972421083327091128166181213
toxicity46262421083215889104136151174207
evaluation48492421083346699114152184206221259298
of516224210833757
inorganic52342421083155391113151183221236268
nanoparticles551824210833769393425210833876115148169194209241257292318
for42712521083185678
Delivery43672521083458196111144178199233
Applications.461925210834180120136151183216237253291329355369
Advanced500725210834179112144182215248288
Drug531325210834667106145
Delivery5476252108346819711239342621083326687121
Reviews.407026210833671103119154205232245
2019;144:112-132.433126210833468100130143173204241253283310340361391421454466
29.39342720085367285
Tang40352721083336199138
W,418827210835867
Fan427127210833262100
W,438627210835867
Lau446927210833165102
J,458727210832436
et463927210833456
al.47112721083324760
Emerging478627210833391126147185200238277
blood–brain-barrier-crossing5079272108338549213117120724726930231735537741745047149350939342821083345575109131168195222237275314
nanotechnology426928210833770108147169203236274312350367405445477
for47672821083185678
brain48652821083396194109147
cancer503328210833164103135169190
theranostics.52442821083226095117150188226253277292324352366
Chemical393429210834078113171186218251266
Society421529210833371104119154176210
Reviews.444029210833570103118153204231245
2019;48(11):2967-3014.470029210833468100130143178214233264292307318354388423456475507541573604617
30.39343020085367186
McKay403330210835486120153184
KM,422930210833591104
Sambrano434530210833265122160182214251289
BL,46473021083356680
Fox47393021083326999
PS,48503021083356780
et494230210833456
al.50103021083324759
Thickness50823021083327185117146185219246272
of536630210833756
superficial5435302108325621011361563934312108317336579110125
basal40713121083387096128143
cell4226312108331647993
carcinoma43313121083316383114128165202259291
(SBCC)46343121083184983123160180
predicts48263121083385992131145176200227
imiquimod50653121083147085123159174230268306
efficacy:5383312108334526987118150181214227
A3934322108341
proposal39943221083386097137176202235251
for42643221083185677
a4360322108332
thickness-based44103221083226075107137177212238265286326359386421460
definition48893221083387390107145160183198236274
of518232210833757
SBCC.525832210833267108146159
British5436322108335577295110136174
Journal393433210832462101122160193208
of415733210833857
Dermatology.422933210834681102161193215252268306345377387
2013;169(3):549-554.463233210833468100130141171202236255289306318353388422445479512547559
31.39343420085366981
Łasińska40303421083326592106144170200234
I,427834210831528
Zielińska43203421083385388103118156182212245
A,458034210834155
Mackiewicz464934210835587119150166201252267299330
J,499334210832437
et504434210833456
al.51143421083324861
Basal51893421083356895128143
cell5347342108331658095
carcinoma:54573421083316485116131393435210833774131162174
Pathology,41203521083346586123161176213251283292
current44243521083306788109142179199
clinical4635352108331466097111142174189
treatment,48363521083214275106127183218255275288
and513635210833168106
potential52543521083387697130167187202233248
use55143521083366296
of393436210833757
lipid4006362108315306984123
nanoparticles.414436210833870108147186219240265280312328362389403
Cancers.456236210834073111143177198225239
2022;14(11):2778.481636210833468101136148178210229261288303315350383417451464
32.39343720085367186
Dourmishev403337210834584122143201216242280315347
LA,43933721083317488
Rusinova44943721083357399114151189221254
D,476137210834556
Botev48303721083357395129161
I.500437210831528
Clinical50453721083395469107122154187202
variants,52603721083316485101133171192220232
stages,55053721083264982393438210833873100113
and406738210833169108
management419538210835890128160199234292327365387
of460238210833756
basal46783821083397298131147
cell4845382108331648095
carcinoma.49603821083316485116131169208266298311
Indian52913821083155392107139177
Dermatology548838210834581102393439210835790111148164202242274
Online422339210834786101116154189
Journal.442839210832462100121160192208221
2013;4(1):12.466439210833468100130141176195227242253283313326